Kyuregyan Karen K, Lopatukhina Maria A, Asadi Mobarkhan Fedor A, Kichatova Vera S, Potemkin Ilya A, Isaeva Olga V, Karlsen Anastasia A, Malinnikova Elena Yu, Kaira Alla N, Kozhanova Tatyana V, Manuylov Victor A, Mazunina Elena P, Bykonia Evgeniia N, Kleymenov Denis A, Ignateva Margarita E, Trotsenko Olga E, Kuznetsova Anna V, Saryglar Anna A, Oorzhak Natalia D, Romanenko Victor V, Mikhailov Mikhail I
Department of Viral Hepatitis, Russian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia.
Laboratory of Viral Hepatitis, Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.
Vaccines (Basel). 2022 Aug 29;10(9):1423. doi: 10.3390/vaccines10091423.
The data on hepatitis A virus (HAV) seroprevalence are critical for the implementation of a universal mass vaccination (UMV) strategy. The latter has not been implemented in Russia; however, regional child vaccination programs have been adopted in some parts of the country. The aim of this study is to assess changes in HAV immunity within the last decade in regions of Russia with different vaccination strategies and different vaccination coverage rates. In regions where UMV has not been implemented and HAV vaccination coverage rates do not exceed the national average, the 50% seroprevalence threshold has shifted in the Moscow region from people aged under 40 years in 2008 to people aged over 59 years in 2020, and from people aged under 30 years to people aged over 40 years in the Khabarovsk region. In two regions (Yakutia and Sverdlovsk), a two-dose-based UMV scheme has been in place since 2011 and 2003, respectively, and in Tuva single-dose child immunization was launched in 2012. These regional programs have resulted in a significant increase in HAV seroprevalence in children and adolescents. In Yakutia, 50% herd immunity had been achieved by 2020 in age groups under 20 years, compared to 20−30% seroprevalence rates in 2008. In the Sverdlovsk region, HAV immunity has increased to >65% over the decade in children aged over 10 years, adolescents and young adults, whereas it declined in older age groups. However, a three-fold drop in HAV immunity has occurred in children under 10 years of age, reflecting a significant decline in vaccination coverage. In Tuva, HAV immunity rates in children under 10 years old increased two-fold to exceed 50% by 2020. These data suggest that UMV should be implemented on a national level. Measures to control vaccination coverage and catch-up vaccination campaigns are recommended in order to maintain the effectiveness of existing HAV vaccination programs.
甲型肝炎病毒(HAV)血清流行率数据对于实施全民大规模疫苗接种(UMV)策略至关重要。俄罗斯尚未实施该策略;然而,该国部分地区已采用了区域性儿童疫苗接种计划。本研究的目的是评估俄罗斯不同疫苗接种策略和不同疫苗接种覆盖率地区在过去十年中HAV免疫力的变化。在未实施UMV且HAV疫苗接种覆盖率未超过全国平均水平的地区,莫斯科地区50%血清流行率阈值已从2008年40岁以下人群转变为2020年59岁以上人群,哈巴罗夫斯克地区则从30岁以下人群转变为40岁以上人群。在两个地区(雅库特和斯维尔德洛夫斯克),分别自2011年和2003年起实施了基于两剂次的UMV计划,图瓦于2012年启动了单剂次儿童免疫接种。这些区域性计划导致儿童和青少年中HAV血清流行率显著上升。在雅库特,到2020年20岁以下年龄组实现了50%的群体免疫,而2008年血清流行率为20 - 30%。在斯维尔德洛夫斯克地区,10岁以上儿童、青少年和年轻人的HAV免疫力在十年间升至>65%,而老年人群体的免疫力下降。然而,10岁以下儿童的HAV免疫力下降了两倍,反映出疫苗接种覆盖率显著下降。在图瓦,到2020年10岁以下儿童的HAV免疫率提高了两倍,超过了50%。这些数据表明应在全国范围内实施UMV。建议采取措施控制疫苗接种覆盖率并开展补种运动,以维持现有HAV疫苗接种计划的有效性。